DHCC and DuBiotech Share Stand at Arab Health 2010

DHCC launches new consultancy services and investment opportunities

Dubai: 25 January, 2010 – TECOM Investments, a member of Dubai Holding, today announced that Dubai Healthcare City (DHCC), the world’s first integrated healthcare free zone, and Dubai Biotechnology and Research Park (DuBiotech), the major life sciences hub in the Middle East, will highlight new opportunities and showcase recent developments at Arab Health 2010, the region’s largest healthcare exhibition.

Running until 29 January at the Dubai International Convention and Exhibition Centre, the current edition of the show is expected to feature an expanded presence with over 2,600 exhibitors.

As a leader in providing the highest quality healthcare which prioritises patient needs, Dubai Healthcare City will launch a suite of new consultancy services including health informatics, medical licensing exams and Primary Source Verification, a system to verify the credentials, experience and qualifications of healthcare professionals. The services will aim to help the GCC healthcare organisations and professionals establish and maintain the highest quality standards that will benefit both the healthcare industry and the patient alike. In addition, DHCC will be highlighting new investment opportunities for leading healthcare providers interested in being part of one of the most ambitious healthcare developments in the world.

Dr. Ayesha Abdullah, Senior Vice-President of Dubai Healthcare City, said:

Since its inception, DHCC has grown into a city of over 90 outpatient centers and diagnostic laboratories, 2 hospitals and over 100 commercial and retail services. We have the highest standards in healthcare and have received wide, international recognition for these standards.

As part of our continued focus on quality and meeting patient needs, we are expanding our services and investment opportunities. If organisations are committed to healthcare best practice and want to be a part of legacy that will change the face of healthcare in the region, they should visit us during Arab Health.”

Dr Marco Baccanti, Executive Director, DuBiotech, said:

Our participation at Arab Health 2010 comes close on the heels of the successful completion of the state-of-the-art Nucleotide Lab Complex. As the largest laboratory facility in the Middle East, it represents a major milestone in the development of DuBiotech. The complex is the ideal place to encourage life sciences initiatives where new ideas are conceptualised and developed into viable businesses.

One of our business partners - MAQUET Middle East - has already commenced operations at the Lab Complex. Visitors to Arab Lab 2010 can look forward to viewing MAQUET’s revolutionary medical technology for operating room systems and intensive care units.

DHCC is home to a wide range of national and international brands and provides a full range of medical services including: immunology, aesthesia, cardiology, dentistry, dermatology, ENT, endocrinology, family medicine, general surgery, internal medicine, neurology, obstetrics, ophthalmology, orthopaedic, physical therapy, plastic surgery, radiology, urology, among others. It is also emerging as a centre of excellence for Complementary and Alternative Medicine services, health informatics and health insurance.

Launched in 2005, the Dubai Biotechnology and Research Park, pursues a mission to create the biggest life sciences cluster in the Middle East. DuBiotech’s latest milestone includes the completion of the state-of-the-art four-storey Nucleotide Laboratory Complex. Comprising 256,000 sq. ft. of leasable area, the ultra-modern Nucleotide Lab Complex is designed to house biotech, life sciences and pharmaceutical activities ranging from research and development to diagnostic, analytical and equipment training activities.

The Arab Health Exhibition and Congress is supported by the UAE Ministry of Health, Dubai Health Authority and the Health Authority Abu Dhabi.

Notes to Editors

Center for Healthcare Planning & Quality (CPQ)

The Center for Healthcare Planning & Quality (CPQ) is the joint endeavor of DHCC and its strategic collaborator Harvard Medical International (HMI) to attain highest international standards of healthcare delivery. Through planning, regulation and quality improvement initiatives in partnership with key stakeholders, CPQ aims to become a leading center of excellence in the region. CPQ ensures that DHCC has the right clinical services mix to meet patient needs, demands and expectations.

International best practices are utilized by ensuring the Licensing of healthcare professionals and facilities, Quality standards for healthcare practice, development of rules and regulations governing clinical practice, Complementary & Alternative Medicine (CAM) Regulations, Health Information Reporting and Analysis System (HIRAS) and Customer Feedback Unit that ensures the highest levels of customer satisfaction.

About Dubai Healthcare City

Dubai Healthcare City (DHCC), a member of TECOM Investments was conceived as the location of choice for quality healthcare and an integrated center of excellence for clinical and wellness services, medical education and research in the Middle East. It is the world’s first healthcare free zone and consists of two phases. The first phase of 4.1 million square feet is now operational with a medical cluster of day-care and outpatient clinics, diagnostic centers, rehabilitation centers, transplantation centers, hospitals and pharmaceutical and equipment suppliers.

DHCC is home to over 80 respected facilities operating to the highest international standards including: The Mohammed Bin Rashid Al Maktoum Academic Medical Center (AMC),The City Hospital, Mayo Clinic, Moorfields Eye Hospital Dubai, Dr. Sulaiman Al Habib Medical Center, the American Academy of Cosmetic Surgery Hospital, Dr. Nicolas & ASP, London Centre for Aesthetic Surgery, Dubai Gynaecology and Fertility Centre, Mughrabi Eye Centre and the German Heart Center. World-leading pharmaceutical companies are also based in DHCC such as Wyeth, Sanofi Aventis, Novartis, AstraZeneca, and Novo Nordisk.

The second phase will feature a dedicated wellness cluster comprised of Wellness centers, Nutrition centers, Resorts, Spas, and Sports Medicine facilities.

For further information, please contact:

Maya El-Hachem
Account Manager
Jiwin Public Relations
Tel: 00971 4 3692925
Email: Maya.Elhachem@Jiwin.ae